Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Foghorn Therapeutics Inc. FHTX

Healthcare Biotechnology
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact... see more

Recent & Breaking News (NDAQ:FHTX)

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

PR Newswire May 16, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

PR Newswire May 10, 2023

Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update

GlobeNewswire May 8, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

PR Newswire May 2, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

PR Newswire April 26, 2023

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference

GlobeNewswire April 25, 2023

Foghorn Therapeutics Provides an Update on FHD-609

GlobeNewswire April 24, 2023

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting

GlobeNewswire April 10, 2023

Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

GlobeNewswire April 6, 2023

Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update

GlobeNewswire March 9, 2023

Foghorn Therapeutics to Participate at Cowen's 43rd Annual Health Care Conference

GlobeNewswire March 1, 2023

Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023

GlobeNewswire January 9, 2023

Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting

GlobeNewswire December 5, 2022

Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference

GlobeNewswire November 22, 2022

Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting

GlobeNewswire November 14, 2022

Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting

GlobeNewswire November 9, 2022

Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update

GlobeNewswire November 8, 2022

Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors

GlobeNewswire October 27, 2022

Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program

GlobeNewswire October 26, 2022

Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit

GlobeNewswire October 20, 2022